-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Emmizumab promotes effective hemostasis
in patients with hemophilia A (PwHA).
It is indicated for routine prevention of bleeding episodes in patients with PwHA, with or without factor (F)VIII inhibitors
.
The article in this report mainly studies the effect
of emilizumab dose increase on poor bleeding control of PwHA.
Data
from seven completed or ongoing phase III studies were pooled.
Assess pharmacokinetics, pharmacodynamics, and bleeding events
before and after dose escalation.
Adverse events (AEs)
with and without dose escalation were compared for PwHA.
In summary, in seven clinical trials, a small number of PwHAs treated with amicilizumab used dose adjustment and were associated with
improved bleeding control in most cases.
Emelizumab with 3 mg/kg QW is tolerated and there is no indication of an increased
risk of prethrombotemia.
Overall, emizumab dose escalation appears to be a potential option for PwHA, where bleeding control is suboptimal in standard dosing regimens, but further investigation
is needed in appropriately designed trials.
Original source:
Schmitt C, Mancuso ME, Chang T, Podolak-Dawidziak M, Petry C, Sidonio R Jr, Yoneyama K, Key NS, Niggli M, Lehle M, Peyvandi F, Oldenburg J.
Emicizumab dose up-titration in case of suboptimal bleeding control in people with haemophilia A.
Haemophilia.
2022 Oct 21.
doi: 10.
1111/hae.
14679.
Epub ahead of print.
PMID: 36271487.
